Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Editas Medicine Achieves Milestone Under Juno Therapeutics Collaboration for Technical Progress Towards Overcoming the Tumor Microenvironment

GlobeNewswire August 9, 2017

Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results

GlobeNewswire August 7, 2017

Biotech Stock Performance Review -- Celgene, Cempra, Editas Medicine, and Epizyme

PR Newswire July 31, 2017

Editas Medicine to Participate in Investor Conferences in June

GlobeNewswire June 13, 2017

Editas Medicine Names Andrew Hirsch to Board of Directors

GlobeNewswire May 31, 2017

10 Biggest Mid-Day Losers For Tuesday

Benzinga.com  May 30, 2017

Research Reports Coverage on Biotech Stocks -- Editas Medicine, Global Blood Therapeutics, Geron, and Infinity Pharma

PR Newswire May 22, 2017

Editas Medicine Announces First Quarter 2017 Results and Update

GlobeNewswire May 15, 2017

Investor Network: Editas Medicine, Inc. to Host Earnings Call

Accesswire May 15, 2017

18 Biggest Mid-Day Gainers For Monday

Benzinga.com  May 15, 2017

Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas

GlobeNewswire May 13, 2017

Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia

GlobeNewswire May 11, 2017

Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results

GlobeNewswire May 8, 2017

Editas Medicine to Present at Investor Conferences in May

GlobeNewswire May 8, 2017

Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting

GlobeNewswire April 24, 2017

Editas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire April 24, 2017

20 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  March 28, 2017

Biotech Stocks on Investors' Radar -- Editas, Intra-Cellular, Aralez Pharma, and Catabasis Pharma

PR Newswire March 21, 2017

20 Biggest Mid-Day Losers For Friday

Benzinga.com  March 17, 2017

Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock

GlobeNewswire March 16, 2017